Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.66 |
| ▸ | DRD2 | P14416 | 4/20 | 0.65 |
| ▸ | DRD3 | P35462 | 4/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.65 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | LPL | P06858 | 2/20 | 0.62 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.62 |
| ▸ | ESR1 | P03372 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | TACR2 | P21452 | 2/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31125326 | 1.00 | PTGS2 (0.66) | PTGS2DRD2DRD3OPRM1OPRD1 | |
| SCHEMBL6558135 | 1.00 | PTGS2 (0.66) | PTGS2DRD2DRD3OPRM1OPRD1 | |
| SCHEMBL530294 | 1.00 | PTGS2 (0.66) | PTGS2DRD2DRD3OPRM1OPRD1 | |
| SCHEMBL1835798 | 1.00 | PTGS2 (0.66) | PTGS2DRD2DRD3OPRM1OPRD1 | |
| SCHEMBL1838969 | 1.00 | PTGS2 (0.66) | PTGS2DRD2DRD3OPRM1OPRD1 | |
| SCHEMBL135991 | 1.00 | PTGS2 (0.66) | PTGS2DRD2DRD3OPRM1OPRD1 | |
| SCHEMBL3358472 | 1.00 | PTGS2 (0.66) | PTGS2DRD2DRD3OPRM1OPRD1 | |
| SCHEMBL649958 | 1.00 | PTGS2 (0.66) | PTGS2DRD2DRD3OPRM1OPRD1 | |
| SCHEMBL1838540 | 1.00 | PTGS2 (0.66) | PTGS2DRD2DRD3OPRM1OPRD1 | |
| SCHEMBL31616474 | 1.00 | PTGS2 (0.66) | PTGS2DRD2DRD3OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0898558-B1 | PROCESS FOR THE CARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS | SHELL INTERNATIONALE RES BR MI (NL) | 2001-11-07 | — | — | EP | claimed |
| US-4900731-A | Antihypertensive phosphate derivatives | AMERICAN CYANAMID COMPANY (US) | 1990-02-13 | — | — | US | claimed |
| US-12577215-B2 | Triazine UV absorbers and a process for the preparation thereof | BASF SE (DE) | 2026-03-17 | — | — | US | disclosed |
| WO-2024204339-A1 | POSITIVE PHOTOSENSITIVE PIGMENT COMPOSITION, CURED PRODUCT, AND ORGANIC EL DISPLAY DEVICE | 東レ株式会社 | 2024-10-03 | — | — | WO | disclosed |
| US-20230088507-A1 | TRIAZINE UV ABSORBERS AND A PROCESS FOR THE PREPARATION THEREOF | BASF SE (DE) | 2023-03-23 | — | — | US | disclosed |
| EP-4081510-A1 | TRIAZINE UV ABSORBERS AND A PROCESS FOR THE PREPARATION THEREOF | BASF SE (DE) | 2022-11-02 | — | — | EP | disclosed |
| CN-114901645-A | Triazine UV absorbent and preparation method thereof | 巴斯夫欧洲公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021130380-A1 | TRIAZINE UV ABSORBERS AND A PROCESS FOR THE PREPARATION THEREOF | BASF SE (DE) | 2021-07-01 | — | — | WO | disclosed |
| CN-104419416-B | Liquid composition containing phosphorescent light-emitting materials | 住友化学株式会社 | 2017-03-29 | — | — | CN | disclosed |
| CN-106133058-A | Polycarbonate resin composition and molded article | 出光兴产株式会社 | 2016-11-16 | — | — | CN | disclosed |
| US-20160083513-A1 | POLYCARBONATE RESIN FOR LIQUID CRYSTAL MEMBERS, POLYCARBONATE RESIN COMPOSITION FOR LIQUID CRYSTAL MEMBERS WHICH CONTAINS SAME, AND LIQUID CRYSTAL MEMBER | IDEMITSU KOSAN CO., LTD. (JP) | 2016-03-24 | — | — | US | disclosed |
| EP-0374513-A2 | Novel bis-arylphosphate ester antagonists of platelet activating factor | AMERICAN CYANAMID COMPANY (US) | 1990-06-27 | — | — | EP | disclosed |
| US-4894367-A | CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1990-01-16 | — | — | US | disclosed |
| US-4883816-A | SULFONYL DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1989-11-28 | — | — | US | disclosed |
| US-4762942-A | AMINO SUBSTITUTED, INNER SALTS | AMERICAN CYANAMID CO. (US) | 1988-08-09 | — | — | US | disclosed |
| US-4699990-A | INNER SALTS | AMERICAN CYANAMID COMPANY (US) | 1987-10-13 | — | — | US | disclosed |
| EP-0070039-A2 | Polymerization catalyst and process for polymerizing alpha-olefins | PHILLIPS PETROLEUM COMPANY (US) | 1983-01-19 | — | — | EP | disclosed |
| US-4243552-A | MAGNESIUM CHLORIDE OR MANGANESE CHLORIDE AND ADJUVANT | PHILLIPS PETROLEUM COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| EP-0012397-A1 | Polymerization catalyst and process for polymerizing alpha-olefins | PHILLIPS PETROLEUM COMPANY (US) | 1980-06-25 | — | — | EP | disclosed |
| US-4200539-A | Fracturing compositions and method of preparing and using the same | HALLIBURTON COMPANY (US) | 1980-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577215-B2 | Triazine UV absorbers and a process for the preparation thereof | CYP2R1, NR2E3, SRD5A2 | PTGS2 1299/4885DRD2 681/4885DRD3 647/4885 |
| US-20230088507-A1 | TRIAZINE UV ABSORBERS AND A PROCESS FOR THE PREPARATION THEREOF | NISCH, DHPS, UMPS | PTGS2 1666/4885DRD2 2801/4885DRD3 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.